RGX 314

Drug Profile

RGX 314

Alternative Names: RGX-314

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REGENXBIO
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Wet age-related macular degeneration

Most Recent Events

  • 04 Jan 2018 Adverse events data from a phase I trial in Wet age-related macular degeneration released by REGENXBIO
  • 15 Mar 2017 REGENXBIO has patents pending for RGX 314 in USA (REGENXBIO, 10-K, March 2017)
  • 01 Mar 2017 Phase-I clinical trials in Wet age-related macular degeneration (In adults, In the elderly) in USA (Ophthalmic) (NCT03066258)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top